Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
survival rates
Biotech
AstraZeneca, Daiichi unpack Dato-DXd's overall survival fail
AstraZeneca and Daiichi have shared the OS data with regulators that are reviewing filings for approval of Dato-DXd.
Nick Paul Taylor
Sep 10, 2024 6:00am
Differences in survival spark FDA hold on Oncopeptides' drug
Jul 8, 2021 8:05am
Takeda takes on multiple myeloma outcomes study, as Ninlaro flounders
Aug 31, 2016 8:00am
